Join 60,000+ competitive exam aspirants
In August 2024, Indian Council of Medical Research (ICMR) and Panacea Biotec announced the initiation of the first-ever Phase 3 clinical trial for which of the following vaccines in India?
Dengue
Malaria
Typhoid
Hepatitis
Dengue
ICMR and Panacea Biotec initiated India's first-ever Phase 3 clinical trial for the tetravalent Dengue vaccine, DengiAll, in August 2024.
Dengue remains a significant public health challenge in India, with no licensed vaccine or antiviral treatment currently available. To address this, the Indian Council of Medical Research (ICMR) collaborated with Panacea Biotec to advance the indigenous DengiAll vaccine. This Phase 3 trial is designed to evaluate the safety and efficacy of the vaccine across various demographics. The initiative marks a milestone in India's vaccine research and development capabilities.
The Indian Council of Medical Research (ICMR) is the apex body in India for the formulation, coordination, and promotion of biomedical research. It functions under the Department of Health Research, Ministry of Health and Family Welfare, Government of India. It was formerly known as the Indian Research Fund Association (IRFA) when it was set up in 1911.
Date of announcement: August 14, 2024
Vaccine Name: DengiAll
Number of study participants: 10,335 healthy adults
Trial scope: 19 clinical trial sites across 18 States and Union Territories
A is correct тАФ The ICMR and Panacea Biotec launched the first-ever Phase 3 clinical trial for the tetravalent Dengue vaccine, DengiAll, in August 2024.
Remember that 'DengiAll' covers all four serotypes of the virus, making it 'tetravalent'; link this to the importance of ICMR's role in self-reliance for essential medical research.